Abstract
The development of new treatments for substance use disorders requires identification of targetable molecular mechanisms. Pathology in glutamatergic neurotransmission system in brain reward circuitry has been implicated in relapse to multiple classes of drugs. Glutamate transporter 1 (GLT-1) crucially regulates glutamatergic signaling by removing excess glutamate from the extrasynaptic space. The purpose of this review is to highlight the effects of addictive drug use on GLT-1 and glutamate uptake, and using GLT-1 as a target in addiction pharmacotherapy. Cocaine, opioids, ethanol, nicotine, amphetamines, and cannabinoids each affect GLT-1 expression and glutamate uptake, and restoring GLT-1 expression with N-acetylcysteine or ceftriaxone shows promise in correcting pre-clinical and clinical manifestations of drug addiction.
Keywords: Accumbens, addiction, ceftriaxone, excitatory amino acid transporter 2, glutamate transport, glutamate transporter 1, glutamate, N-acetylcysteine.
CNS & Neurological Disorders - Drug Targets
Title:Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders
Volume: 14 Issue: 6
Author(s): Douglas J. Roberts-Wolfe and Peter W. Kalivas
Affiliation:
Keywords: Accumbens, addiction, ceftriaxone, excitatory amino acid transporter 2, glutamate transport, glutamate transporter 1, glutamate, N-acetylcysteine.
Abstract: The development of new treatments for substance use disorders requires identification of targetable molecular mechanisms. Pathology in glutamatergic neurotransmission system in brain reward circuitry has been implicated in relapse to multiple classes of drugs. Glutamate transporter 1 (GLT-1) crucially regulates glutamatergic signaling by removing excess glutamate from the extrasynaptic space. The purpose of this review is to highlight the effects of addictive drug use on GLT-1 and glutamate uptake, and using GLT-1 as a target in addiction pharmacotherapy. Cocaine, opioids, ethanol, nicotine, amphetamines, and cannabinoids each affect GLT-1 expression and glutamate uptake, and restoring GLT-1 expression with N-acetylcysteine or ceftriaxone shows promise in correcting pre-clinical and clinical manifestations of drug addiction.
Export Options
About this article
Cite this article as:
Roberts-Wolfe J. Douglas and Kalivas W. Peter, Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150529144655
DOI https://dx.doi.org/10.2174/1871527314666150529144655 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology The Role of Mitochondrial Function in Glutamate-Dependent Metabolism in Neuronal Cells
Current Pharmaceutical Design Docking-Related Survey on Natural-Product-Based New Monoamine Oxidase Inhibitors and Their Therapeutic Potential
Combinatorial Chemistry & High Throughput Screening Astroglial Connexins as a Therapeutic Target for Alzheimer's Disease
Current Pharmaceutical Design The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research Patent Selections
Recent Patents on Biomarkers Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Mini-Reviews in Medicinal Chemistry Role of Methylene Blue in Trauma Neuroprotection and Neuropsychiatric Diseases
CNS & Neurological Disorders - Drug Targets Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Current Medicinal Chemistry Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues
Anti-Cancer Agents in Medicinal Chemistry A Cross-entropy-based Method for Essential Protein Identification in Yeast Protein-protein Interaction Network
Current Bioinformatics Population Studies of Association Between Lithium and Risk of Neurodegenerative Disorders
Current Alzheimer Research Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Experimental Developments and Review of Recent Patents for the Repair of Skeletal Muscles by Methods of Regenerative Medicine
Recent Patents on Regenerative Medicine